Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Setting the cytokine trap for autoimmunity

Nature Medicine volume 9, pages 20–22 (2003)Cite this article

Agents that block the action of specific cytokines have changed the lives of many patients with rheumatoid arthritis and other autoimmune disorders. But frequent self-injections or injections by a physician during a clinic visit are required. Now a new class of anti-cytokine that may bypass such problems appears on the horizon (pages 47–52).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Blocking IL-1 activity.
Figure 2: Cytokine trap treats inflammation in arthritic mice.

Courtesy of E. Koehler-Stec, T. Sterlacci and S. Staton

References

  1. Economides, A.N. et al. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003).

    Article  CAS  Google Scholar 

  2. Stahl, N. & Yancopoulos, G.D. The alphas, betas, and kinases of cytokine receptor complexes. Cell 74, 587–590 (1993).

    Article  CAS  Google Scholar 

  3. Frishman, J.I. et al. Tumor necrosis factor (TNF)-α-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. J. Infect. Dis. 182, 1722–1730 (2000).

    Article  CAS  Google Scholar 

  4. Preas, H.L., 2nd et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 88, 2465–2472 (1996).

    CAS  PubMed  Google Scholar 

  5. Moreland, L.W. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).

    Article  CAS  Google Scholar 

  6. Fleischman, R. et al. A safety trial of anakinra: Recombinant interleukin-1 receptor antagonist in a large, placebo controlled heterogenous population of patients with rheumatoid arthritis. Arthrit. Rheumat. (in the press).

  7. Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthrit. Rheum. 41, 2196–2204 (1998).

    Article  CAS  Google Scholar 

  8. Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center Division of Infectious Diseases,

    Charles A. Dinarello

Authors
  1. Charles A. Dinarello
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dinarello, C. Setting the cytokine trap for autoimmunity. Nat Med 9, 20–22 (2003). https://doi.org/10.1038/nm0103-20

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0103-20

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing